Shigetoshi Sano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shigetoshi Sano has a total of 329 co-authors. Here are the top co-authors by number of shared publications:
Mikiro Takaishi
Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan
21 shared publications- Kimiko Nakajima
Department of Dermatology Kochi Medical School, Kochi University Kochi Japan
18 shared publications - Hideki Nakajima
Department of Dermatology, Kochi Medical School Kochi University Kochi Japan
14 shared publications Kimiko Nakajima
Department of Dermatology Kochi Medical School, Kochi University Nankoku Japan
13 shared publicationsMayuko Yamamoto
Department of Dermatology Kochi Medical School, Kochi University Nankoku Japan
10 shared publications- Akimichi Morita
Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan
9 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wiley in The Journal of Dermatology
Clinical and Patient‐Reported Factors Associated With Impaired Quality of Life in Japanese Patients With Vitiligo: A Multicenter Questionnaire Study Using VitiQoL
Vitiligo can cause a substantial psychosocial burden. However, the clinical and patient‐reported features associated with impaired disease‐specific quality of life (QoL) in Japanese patients remain incompletely characterized. We conducted a multicenter, cross‐sectional questionnaire study to examine the associations between the Vitiligo‐specific Quality‐of‐Life (VitiQoL) instrument and clinical variables reported by patients and physicians. A total of 255 questionnaires were collected, and 227 patients with complete VitiQoL data were included in the main analysis. The mean VitiQoL total score was 40.6 ± 22.4. Higher VitiQoL scores were associated with female sex, exposed‐site involvement, and border hyperpigmentation, with scores increasing progressively with the number of involved exposed regions. VitiQoL scores showed a trend toward an inverse correlation with age. Lesion‐associated symptoms were also associated with higher VitiQoL scores, whereas non‐lesional skin symptoms were not. Lesion‐associated symptoms were associated with physician‐rated disease severity. Treatment response assessed by either patients or physicians was not associated with VitiQoL scores. In multivariable analysis, female sex, younger age, a greater number of exposed regions, and border hyperpigmentation were independently associated with higher VitiQoL scores, whereas physician‐rated disease severity and lesion‐associated symptoms were not. These findings highlight the multifactorial nature of QoL impairment in vitiligo and the importance of incorporating both clinical and patient‐reported features into the assessment of QoL beyond repigmentation‐based treatment response.
- 18 September 2026
- Published by Wiley in The Journal of Dermatology
Open AccessClinical and Patient‐Reported Factors Associated With Impaired Quality of Life in Japanese Patients With Vitiligo: A Multicenter Questionnaire Study Using VitiQoL
Vitiligo can cause a substantial psychosocial burden. However, the clinical and patient‐reported features associated with impaired disease‐specific quality of life (QoL) in Japanese patients remain incompletely characterized. We conducted a multicenter, cross‐sectional questionnaire study to examine the associations between the Vitiligo‐specific Quality‐of‐Life (VitiQoL) instrument and clinical variables reported by patients and physicians. A total of 255 questionnaires were collected, and 227 patients with complete VitiQoL data were included in the main analysis. The mean VitiQoL total score was 40.6 ± 22.4. Higher VitiQoL scores were associated with female sex, exposed‐site involvement, and border hyperpigmentation, with scores increasing progressively with the number of involved exposed regions. VitiQoL scores showed a trend toward an inverse correlation with age. Lesion‐associated symptoms were also associated with higher VitiQoL scores, whereas non‐lesional skin symptoms were not. Lesion‐associated symptoms were associated with physician‐rated disease severity. Treatment response assessed by either patients or physicians was not associated with VitiQoL scores. In multivariable analysis, female sex, younger age, a greater number of exposed regions, and border hyperpigmentation were independently associated with higher VitiQoL scores, whereas physician‐rated disease severity and lesion‐associated symptoms were not. These findings highlight the multifactorial nature of QoL impairment in vitiligo and the importance of incorporating both clinical and patient‐reported features into the assessment of QoL beyond repigmentation‐based treatment response.
- 31 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8)
Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025)
Vitiligo is a common acquired hypopigmented disorder characterized by melanocyte damage and/or loss, primarily resulting from excessive oxidative stress and dysregulated immune responses targeting melanocytes. The initial guidelines for the diagnosis and treatment of vitiligo in Japan were published in Japanese in 2012 and in English in 2013 to provide clinical evidence for vitiligo management. Since then, there has been a substantial accumulation of pathological research and therapeutic evidence. The second guidelines for the diagnosis and treatment of vitiligo in Japan (2025) are presented as an updated resource for clinicians, incorporating worldwide expert recommendations and recent advances in basic and clinical research. These guidelines aim to provide updated knowledge for individuals with vitiligo, public health professionals, scientists, and dermatologists.
- 31 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8)
Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025)
Vitiligo is a common acquired hypopigmented disorder characterized by melanocyte damage and/or loss, primarily resulting from excessive oxidative stress and dysregulated immune responses targeting melanocytes. The initial guidelines for the diagnosis and treatment of vitiligo in Japan were published in Japanese in 2012 and in English in 2013 to provide clinical evidence for vitiligo management. Since then, there has been a substantial accumulation of pathological research and therapeutic evidence. The second guidelines for the diagnosis and treatment of vitiligo in Japan (2025) are presented as an updated resource for clinicians, incorporating worldwide expert recommendations and recent advances in basic and clinical research. These guidelines aim to provide updated knowledge for individuals with vitiligo, public health professionals, scientists, and dermatologists.
- 29 May 2026
- Published by Elsevier in Journal of Dermatological Science
- Vol. 123 (2) , 56-62
A zinc deficiency leads to non-inflammatory pruritus by modifying opioid receptor signaling
- 29 May 2026
- Published by Elsevier in Journal of Dermatological Science
- Vol. 123 (2) , 56-62
A zinc deficiency leads to non-inflammatory pruritus by modifying opioid receptor signaling
- Open Access
Detection of Vaccine-Derived Spike Protein Associated with Immune Cell Infiltration in the Heart and Liver: A Report of Two Cases
The rapid development and deployment of COVID-19 genetic vaccines have raised significant concerns regarding their safety and potential to trigger immune reactions against self-tissues. This paper provides a comprehensive histopathologically supported analysis of how the synthesis of the vaccine-derived spike protein can trigger such reactions beyond the injection site, characterized by robust immune cell recruitment. We examine these immune responses based on histopathological evidence that delineates a pattern consistent with self-directed immune activity, including vaccine-associated myocarditis. In this regard, we report two representative cases, marked by immune-cell infiltration, triggered by the synthesis of the vaccine-derived spike protein in the myocardium and in the liver, respectively. Additionally, we provide a detailed characterization of the process and the immune cells involved in these reactions, based on histopathological findings. Understanding these mechanisms is essential for accurately assessing the potential implications of these vaccination technologies on human health. By emphasizing the need for further research into the pharmacokinetics and off-target effects of COVID-19 genetic vaccines, this paper aims to deepen our understanding of their safety profiles and inform future vaccine development.
Open AccessDetection of Vaccine-Derived Spike Protein Associated with Immune Cell Infiltration in the Heart and Liver: A Report of Two Cases
The rapid development and deployment of COVID-19 genetic vaccines have raised significant concerns regarding their safety and potential to trigger immune reactions against self-tissues. This paper provides a comprehensive histopathologically supported analysis of how the synthesis of the vaccine-derived spike protein can trigger such reactions beyond the injection site, characterized by robust immune cell recruitment. We examine these immune responses based on histopathological evidence that delineates a pattern consistent with self-directed immune activity, including vaccine-associated myocarditis. In this regard, we report two representative cases, marked by immune-cell infiltration, triggered by the synthesis of the vaccine-derived spike protein in the myocardium and in the liver, respectively. Additionally, we provide a detailed characterization of the process and the immune cells involved in these reactions, based on histopathological findings. Understanding these mechanisms is essential for accurately assessing the potential implications of these vaccination technologies on human health. By emphasizing the need for further research into the pharmacokinetics and off-target effects of COVID-19 genetic vaccines, this paper aims to deepen our understanding of their safety profiles and inform future vaccine development.
- Open Access
- 17 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Aberrant laminin signaling drives melanocyte dedifferentiation and unveils a tractable therapeutic target in vitiligo
Vitiligo is an acquired depigmenting disorder characterized by progressive melanocyte loss, yet its cellular mechanisms remain incompletely understood. Here, we identify a melanocyte dedifferentiation-like shift as a potentially reversible pathogenic mechanism. In healthy skin, melanocytes reside within a basement membrane niche defined by dystroglycan-laminin-211 adhesion. In vitiligo, extracellular matrix remodeling with reduced laminin-211 and increased laminin-332 is associated with a shift toward integrin α3β1-laminin-332 interactions. This alteration correlates with melanocyte dedifferentiation-like changes, together with Rho-F-actin remodeling, and coordinated alterations in Hippo, MAPK, and c-Jun signaling. Affected melanocytes exhibit reduced pigmentation and features of neural crest-like states, including multilineage potential. Importantly, these changes are partially reversible. Pharmacological modulation restored melanocyte differentiation and pigmentation in mouse models and ex vivo human skin, with JAK inhibition also promoting redifferentiation. These findings identify a microenvironment-driven mechanism in vitiligo and suggest potential therapeutic strategies.
- 17 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAberrant laminin signaling drives melanocyte dedifferentiation and unveils a tractable therapeutic target in vitiligo
Vitiligo is an acquired depigmenting disorder characterized by progressive melanocyte loss, yet its cellular mechanisms remain incompletely understood. Here, we identify a melanocyte dedifferentiation-like shift as a potentially reversible pathogenic mechanism. In healthy skin, melanocytes reside within a basement membrane niche defined by dystroglycan-laminin-211 adhesion. In vitiligo, extracellular matrix remodeling with reduced laminin-211 and increased laminin-332 is associated with a shift toward integrin α3β1-laminin-332 interactions. This alteration correlates with melanocyte dedifferentiation-like changes, together with Rho-F-actin remodeling, and coordinated alterations in Hippo, MAPK, and c-Jun signaling. Affected melanocytes exhibit reduced pigmentation and features of neural crest-like states, including multilineage potential. Importantly, these changes are partially reversible. Pharmacological modulation restored melanocyte differentiation and pigmentation in mouse models and ex vivo human skin, with JAK inhibition also promoting redifferentiation. These findings identify a microenvironment-driven mechanism in vitiligo and suggest potential therapeutic strategies.
- 4 October 2025
- Published by Elsevier in Journal of Dermatological Science
- Vol. 120 (2) , 71-73
A case of metastatic breast carcinoma to the skin expressing SARS-CoV-2 spike protein possibly derived from mRNA vaccine
- 4 October 2025
- Published by Elsevier in Journal of Dermatological Science
- Vol. 120 (2) , 71-73
A case of metastatic breast carcinoma to the skin expressing SARS-CoV-2 spike protein possibly derived from mRNA vaccine
- 19 September 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1) , 71-85
Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics
Although biologic agents have significantly improved therapeutic outcomes for psoriasis, their long‐term use can be burdensome for patients due to high costs, parenteral administration, and safety concerns. Consequently, some patients in remission wish to switch to alternative maintenance therapies to reduce this treatment burden. Based on our prior survey, the present prospective, open‐label, single‐arm, multicenter clinical study focused on patients with plaque psoriasis with or without psoriatic arthritis (PsA) who had achieved remission with biologics but were hesitant to continue this therapy. We evaluated the efficacy and safety of transitioning to apremilast, a phosphodiesterase 4 inhibitor, for maintaining remission. Among 209 patients initially surveyed, 46 were enrolled, and 44 were included in the efficacy analysis. The study cohort comprised 30 males and 16 females, with a mean disease duration of 19.2 years, a mean Psoriasis Area and Severity Index (PASI) score of 0.36, and a mean Dermatology Life Quality Index (DLQI) score of 0.30 at baseline. At 24 weeks, the Kaplan–Meier (KM) median time to relapse was not reached overall; the KM remission‐maintenance rate was 63.6% (95% CI, 48.8–76.3) when adverse event related discontinuations were counted as events, and 75.7% (59.7–86.8) when censored. The corresponding restricted mean survival time through 24 weeks was 20.31 and 22.03 weeks, respectively. Patients who maintained remission consistently demonstrated low scores (≤ 1) across PASI, Body Surface Area, DLQI, and American College of Rheumatology components throughout the observation period. A total of 34 adverse events occurred in 23 patients, most commonly diarrhea, vomiting, and headache. All were mild, no serious events were observed, and all resolved without sequelae. In conclusion, for patients with plaque psoriasis with or without PsA who have achieved remission but are concerned about the burdens of long‐term biologic therapy, transitioning to apremilast represents an effective and viable strategy.
- 19 September 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1) , 71-85
Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics
Although biologic agents have significantly improved therapeutic outcomes for psoriasis, their long‐term use can be burdensome for patients due to high costs, parenteral administration, and safety concerns. Consequently, some patients in remission wish to switch to alternative maintenance therapies to reduce this treatment burden. Based on our prior survey, the present prospective, open‐label, single‐arm, multicenter clinical study focused on patients with plaque psoriasis with or without psoriatic arthritis (PsA) who had achieved remission with biologics but were hesitant to continue this therapy. We evaluated the efficacy and safety of transitioning to apremilast, a phosphodiesterase 4 inhibitor, for maintaining remission. Among 209 patients initially surveyed, 46 were enrolled, and 44 were included in the efficacy analysis. The study cohort comprised 30 males and 16 females, with a mean disease duration of 19.2 years, a mean Psoriasis Area and Severity Index (PASI) score of 0.36, and a mean Dermatology Life Quality Index (DLQI) score of 0.30 at baseline. At 24 weeks, the Kaplan–Meier (KM) median time to relapse was not reached overall; the KM remission‐maintenance rate was 63.6% (95% CI, 48.8–76.3) when adverse event related discontinuations were counted as events, and 75.7% (59.7–86.8) when censored. The corresponding restricted mean survival time through 24 weeks was 20.31 and 22.03 weeks, respectively. Patients who maintained remission consistently demonstrated low scores (≤ 1) across PASI, Body Surface Area, DLQI, and American College of Rheumatology components throughout the observation period. A total of 34 adverse events occurred in 23 patients, most commonly diarrhea, vomiting, and headache. All were mild, no serious events were observed, and all resolved without sequelae. In conclusion, for patients with plaque psoriasis with or without PsA who have achieved remission but are concerned about the burdens of long‐term biologic therapy, transitioning to apremilast represents an effective and viable strategy.
- 25 July 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10) , 1545-1554
Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics
The introduction of biological agents has significantly improved therapeutic outcomes for patients with psoriasis. However, the long‐term use of biologics may present substantial burdens for patients due to various factors. Therefore, identifying effective maintenance therapy is important to reduce treatment burden while maintaining disease control. We conducted a questionnaire‐based study to assess patient satisfaction, quality of life, and concerns with ongoing biologic therapy, an oral treatment, as maintenance therapy in psoriasis vulgaris patients in remission. We first surveyed patient‐reported outcomes, including treatment satisfaction, quality of life, and concerns with ongoing biologic therapy. Between December 2020 and June 2022, a total of 209 patients with psoriasis vulgaris, including those with joint symptoms, were enrolled. The mean Psoriasis Area and Severity Index score was 0.30, and the mean Dermatology Life Quality Index score was 0.25, confirming that patients remained in remission. The majority of patients (96.1%) reported overall satisfaction with biologic therapy, while 98.6% were satisfied with the therapeutic efficacy. However, 18.2% of patients reported pain, distress, or anxiety related to injection administration, 8.2% expressed concerns regarding treatment safety, and 38.0% reported dissatisfaction with the financial burden of biologic therapy. While patient satisfaction with the therapeutic effects of biologic agents was high, concerns regarding treatment cost and uncertainty about the duration of therapy remained prominent. These findings underscore the need for alternative maintenance strategies, such as oral therapies, to optimize long‐term disease management and improve patient adherence and quality of life. Although this questionnaire‐based analysis did not include the administration of oral therapies such as apremilast, it provides insights that may support future consideration of oral maintenance treatments for patients with psoriasis. Trial Registration: Japan Registry of Clinical Trials: jRCTs031200238
- 25 July 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (10) , 1545-1554
Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics
The introduction of biological agents has significantly improved therapeutic outcomes for patients with psoriasis. However, the long‐term use of biologics may present substantial burdens for patients due to various factors. Therefore, identifying effective maintenance therapy is important to reduce treatment burden while maintaining disease control. We conducted a questionnaire‐based study to assess patient satisfaction, quality of life, and concerns with ongoing biologic therapy, an oral treatment, as maintenance therapy in psoriasis vulgaris patients in remission. We first surveyed patient‐reported outcomes, including treatment satisfaction, quality of life, and concerns with ongoing biologic therapy. Between December 2020 and June 2022, a total of 209 patients with psoriasis vulgaris, including those with joint symptoms, were enrolled. The mean Psoriasis Area and Severity Index score was 0.30, and the mean Dermatology Life Quality Index score was 0.25, confirming that patients remained in remission. The majority of patients (96.1%) reported overall satisfaction with biologic therapy, while 98.6% were satisfied with the therapeutic efficacy. However, 18.2% of patients reported pain, distress, or anxiety related to injection administration, 8.2% expressed concerns regarding treatment safety, and 38.0% reported dissatisfaction with the financial burden of biologic therapy. While patient satisfaction with the therapeutic effects of biologic agents was high, concerns regarding treatment cost and uncertainty about the duration of therapy remained prominent. These findings underscore the need for alternative maintenance strategies, such as oral therapies, to optimize long‐term disease management and improve patient adherence and quality of life. Although this questionnaire‐based analysis did not include the administration of oral therapies such as apremilast, it provides insights that may support future consideration of oral maintenance treatments for patients with psoriasis. Trial Registration: Japan Registry of Clinical Trials: jRCTs031200238
- 26 May 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (3) , e70028
Alteration of Hair Melanin in Patients With Mowat–Wilson Syndrome: The Role of the ZEB2 Gene in Regulating Melanogenesis Through SLC45A2
Mowat–Wilson syndrome (MOWS) is a congenital disease characterized by intellectual disability, delayed motor development, characteristic facial features, epilepsy, and a wide spectrum of neurocristopathies. MOWS is caused by de novo heterozygous loss‐of‐function mutations or deletions in the zinc finger E‐box‐binding homeobox2 (ZEB2) gene, which is a multifunctional regulator of neuronal development and cancer progression/metastasis through epithelial‐to‐mesenchymal transition. We recognized that patients with MOWS have brown to red hair. In the present study, we report that hair from patients with MOWS has reduced eumelanin and elevated pheomelanin contents, resulting in an increased pheomelanin‐to‐eumelanin ratio. Furthermore, ZEB2‐mutated human epidermal melanocytes show a predominance of pheomelanin biosynthesis over eumelanin and decreased expression of SLC45A2, the gene responsible for oculocutaneous albinism 4. Our results suggest that ZEB2 plays a role in mixed melanogenesis by regulating the melanosomal ion transporter gene, SLC45A2.
- 26 May 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (3) , e70028
Alteration of Hair Melanin in Patients With Mowat–Wilson Syndrome: The Role of the ZEB2 Gene in Regulating Melanogenesis Through SLC45A2
Mowat–Wilson syndrome (MOWS) is a congenital disease characterized by intellectual disability, delayed motor development, characteristic facial features, epilepsy, and a wide spectrum of neurocristopathies. MOWS is caused by de novo heterozygous loss‐of‐function mutations or deletions in the zinc finger E‐box‐binding homeobox2 (ZEB2) gene, which is a multifunctional regulator of neuronal development and cancer progression/metastasis through epithelial‐to‐mesenchymal transition. We recognized that patients with MOWS have brown to red hair. In the present study, we report that hair from patients with MOWS has reduced eumelanin and elevated pheomelanin contents, resulting in an increased pheomelanin‐to‐eumelanin ratio. Furthermore, ZEB2‐mutated human epidermal melanocytes show a predominance of pheomelanin biosynthesis over eumelanin and decreased expression of SLC45A2, the gene responsible for oculocutaneous albinism 4. Our results suggest that ZEB2 plays a role in mixed melanogenesis by regulating the melanosomal ion transporter gene, SLC45A2.
- 18 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2261-2271.e15
A Newly Identified Spliceosomal Protein AHED Is Essential for Homeostasis of the Epidermis
- 18 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2261-2271.e15
A Newly Identified Spliceosomal Protein AHED Is Essential for Homeostasis of the Epidermis